CompletedNot Applicable

A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia

United Kingdom103 participantsStarted 2016-12

Plain-language summary

Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and epidemiological purposes. This study applies next-generation sequencing based metagenomic techniques to patients with extremely severe community acquired pneumonia, to investigate the microbiome of severe community acquired pneumonia and evaluate metagenomic approaches as diagnostic tools.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 or over * Admitted to a participating severe respiratory failure centre or ICU * Admitted due to community acquired pneumonia (CAP) according to clinical and radiological criteria * Tracheal intubation, receiving mechanical ventilation +/- ECMO * Requires bronchoscopy as part of routine diagnostic care plan * Bronchoscopy takes place within 72 hours of first admission to hospital Exclusion Criteria: * Any current or previous condition/circumstance that, in the opinion of the investigator or study nurse, may put the individual at risk if participating * Patients receiving end of life care * Hospitalisation within the previous 28 days (not including pre-ECMO hospitalisation for ECMO patients) * Consent or assent not given

What they're measuring

Detection of pathogens by metagenomic sequencing applied to bronchoalveolar lavage samples

Timeframe: 28 days (From time of enrollment up until end of inclusion)

Trial details

NCT IDNCT02963142

SponsorImperial College London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10